{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:50:27Z","timestamp":1762923027766,"version":"3.45.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":215,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016930","name":"Ferring Research Institute Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.crphar.2023.100163","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T21:54:26Z","timestamp":1691531666000},"page":"100163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis"],"prefix":"10.1016","volume":"5","author":[{"given":"Stan","family":"Bukofzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward E.","family":"Cable","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.crphar.2023.100163_bib1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.12.6.1047","article-title":"Hemodynamic changes associated with fluid retention induced in noncardiac subjects by corticotropin (ACTH) and cortisone; comparison with the hemodynamic changes of congestive heart failure","volume":"12","author":"Albert","year":"1955","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.crphar.2023.100163_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.crphar.2023.100163_bib39","article-title":"OCE-205, a novel, selective vasopressin receptor mixed agonist-antagonist: safety, tolerability, and PK\/PD from a phase 1 study","volume":"43","author":"Bagger","year":"2023","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"10.1016\/j.crphar.2023.100163_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2110-5820-3-12","article-title":"Clinical use of lactate monitoring in critically ill patients","volume":"3","author":"Bakker","year":"2013","journal-title":"Ann. Intensive Care"},{"issue":"2","key":"10.1016\/j.crphar.2023.100163_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1677\/joe.0.1560223","article-title":"Structural bases of vasopressin\/oxytocin receptor function","volume":"156","author":"Barberis","year":"1998","journal-title":"J. Endocrinol."},{"issue":"2","key":"10.1016\/j.crphar.2023.100163_bib5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.crphar.2023.100163_bib6","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crphar.2023.100163_bib7","series-title":"The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment","first-page":"379","article-title":"Advantages and limitations of commonly used nonhuman primate species in research and development of biopharmaceuticals","author":"Cauvin","year":"2015"},{"key":"10.1016\/j.crphar.2023.100163_bib8","series-title":"Ascites & Renal Dysfunction in Liver Disease","first-page":"215","article-title":"Experimental models of cirrhosis and ascites","author":"Claria","year":"2005"},{"issue":"Pt A","key":"10.1016\/j.crphar.2023.100163_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2016.08.027","article-title":"Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: implications for its safety profile","volume":"113","author":"Colson","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.crphar.2023.100163_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0976500X231175220","article-title":"Selective partial agonism of vasopressin 1a receptors in vitro by OCE-205","volume":"14","author":"Croston","year":"2023","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"4","key":"10.1016\/j.crphar.2023.100163_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2125.2007.02921.x","article-title":"Ischaemic complications of glypressin in liver disease: a case series","volume":"64","author":"Donnellan","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.crphar.2023.100163_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.crphar.2023.100163_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-018-0022-7","article-title":"Hepatorenal syndrome","volume":"4","author":"Gin\u00e8s","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.crphar.2023.100163_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1053\/j.ajkd.2019.10.010","article-title":"Critical care nephrology: core curriculum 2020","volume":"75","author":"Griffin","year":"2020","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.crphar.2023.100163_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/bjaceaccp\/mkv017","article-title":"Splanchnic circulation","volume":"16","author":"Harper","year":"2015","journal-title":"BJA Education"},{"issue":"4","key":"10.1016\/j.crphar.2023.100163_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1152\/japplphysiol.00825.2006","article-title":"Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways","volume":"102","author":"Henderson","year":"2007","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.crphar.2023.100163_bib16","first-page":"CD011532","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome","volume":"9","author":"Israelsen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.crphar.2023.100163_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JEP.S146034","article-title":"In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2","volume":"10","author":"Jamil","year":"2018","journal-title":"J. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/j.crphar.2023.100163_bib18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1345\/aph.1L373","article-title":"Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications","volume":"43","author":"Karwa","year":"2009","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.crphar.2023.100163_bib19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","article-title":"Vasopressin V1a and V1b receptors: from molecules to physiological systems","volume":"92","author":"Koshimizu","year":"2012","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.crphar.2023.100163_bib20","doi-asserted-by":"crossref","first-page":"F1295","DOI":"10.1152\/ajprenal.90407.2008","article-title":"Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects","volume":"295","author":"Krag","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.crphar.2023.100163_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/dkg046","article-title":"Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys","volume":"51","author":"Lin","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.crphar.2023.100163_bib22","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/CCM.0000000000004617","article-title":"Fluid overload and mortality in adult critical care patients: a systematic review and meta-analysis of observational studies","volume":"48","author":"Messmer","year":"2020","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.crphar.2023.100163_bib23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/liv.13589","article-title":"The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis","volume":"38","author":"Moller","year":"2018","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.crphar.2023.100163_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00000542-200501000-00016","article-title":"Comparative cardiac effects of terlipressin, vasopressin, and norepinephrine on an isolated perfused rabbit heart","volume":"102","author":"Ouattara","year":"2005","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.crphar.2023.100163_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajp.22281","article-title":"Why primate models matter","volume":"76","author":"Phillips","year":"2014","journal-title":"Am. J. Primatol."},{"issue":"3","key":"10.1016\/j.crphar.2023.100163_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/bod.2510090304","article-title":"Effect of acute water deprivation on renal function in rats","volume":"9","author":"Prasad","year":"1988","journal-title":"Biopharm. Drug Dispos."},{"issue":"9","key":"10.1016\/j.crphar.2023.100163_bib27","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2460\/javma.1986.189.09.1044","article-title":"Single-injection method for evaluation of renal function with 3H-inulin and 14C-tetraethylammonium bromide in conscious unrestrained Sprague-Dawley rats","volume":"189","author":"Radin","year":"1986","journal-title":"J. Am. Vet. Med. Assoc."},{"issue":"2","key":"10.1016\/j.crphar.2023.100163_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/jpp.JPP_23_18","article-title":"Terlipressin-induced ischemic complications: a systematic review of published case reports","volume":"9","author":"Sarma","year":"2018","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"2","key":"10.1016\/j.crphar.2023.100163_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJMra032401","article-title":"Acute renal failure and sepsis","volume":"351","author":"Schrier","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.crphar.2023.100163_bib30","first-page":"759","article-title":"Cirrhosis: diagnosis and management","volume":"100","author":"Smith","year":"2019","journal-title":"Am. Fam. Physician"},{"issue":"5","key":"10.1016\/j.crphar.2023.100163_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI102634","article-title":"The effect of epinephrine (USP), L-epinephrine, and L -norepinephrine on glomerular filtration rate, renal plasma flow, and the urinary excretion of sodium, potassium, and water in normal man","volume":"31","author":"Smythe","year":"1952","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.crphar.2023.100163_bib32","first-page":"1187","article-title":"Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther","volume":"316","author":"Tahara","year":"2006","journal-title":"Mar"},{"issue":"Suppl. 1","key":"10.1016\/j.crphar.2023.100163_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40261-022-01149-3","article-title":"Management of liver decompensation in advanced liver disease (renal impairment, liver failure, adrenal insufficiency, cardiopulmonary complications)","volume":"42","author":"Tellez","year":"2022","journal-title":"Clin. Drug Invest."},{"year":"2022","series-title":"TERLIVAZ [terlipressin] for Injection","key":"10.1016\/j.crphar.2023.100163_bib34"},{"issue":"3","key":"10.1016\/j.crphar.2023.100163_bib35","first-page":"599","article-title":"The vasopressin system: physiology and clinical strategies. Anesthesiology","volume":"105","author":"Treschan","year":"2006","journal-title":"Sep"},{"year":"2022","series-title":"FDA Approves Treatment to Improve Kidney Function in Adults with Hepatorenal Syndrome","key":"10.1016\/j.crphar.2023.100163_bib36"},{"issue":"3","key":"10.1016\/j.crphar.2023.100163_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/jtbi.1996.0130","article-title":"Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: a theory","volume":"181","author":"Zhu","year":"1996","journal-title":"J. Theor. Biol."}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257123000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257123000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:46:24Z","timestamp":1762922784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257123000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":39,"alternative-id":["S2590257123000111"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2023.100163","relation":{},"ISSN":["2590-2571"],"issn-type":[{"type":"print","value":"2590-2571"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2023.100163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100163"}}